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Abstract
Introduction: Sarcoidosis is a granulomatous disease that mostly involves the lungs. Its association
with malignancies has been well documented. Several mechanisms have been proposed that may
underlie this concurrence including triggering tumour antigens and defective cellular immunity.
Case presentations: We briefly review the literature on malignancy associated sarcoidosis and
report two female lymphoma patients of 49 and 56 years of age who, during their course of disease,
developed sarcoidosis that was misinterpreted as a lymphoma relapse on positron emission
tomography-computed tomography.
Conclusion: We hypothesise that T cell dysfunction and exposure to tumour associated antigens
might be the underlying mechanisms of development of sarcoidosis in patients with lymphoma.
Positron emission tomography-positive lesions do not always indicate malignancy and therefore a
tissue biopsy is always mandatory to confirm the diagnosis.
Introduction
Sarcoidosis is an uncommon granulomatous disease
primarily manifesting itself with pulmonary involvement.
Any organ, including the eye, central nervous system, and
even gonads can be involved. Systemic sarcoidosis, in
particular localised sarcoidal reaction, is well documented
in association with malignancies. We report two patients
who developed sarcoidal reactions in association with
lymphoma.
Case 1
A 56-year-old woman presented with enlarged right
cervical lymph nodes (LN) that failed to regress following
appropriate treatment with antibiotics. The largest LN
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(page number not for citation purposes)measured 3.8 cm in diameter. A fine needle aspiration of
the LN was highly suspicious for Hodgkin’s lymphoma
(HL). The excisional biopsy of the LN revealed complete
architectural effacement with scattered Reed-Sternberg
(RS) cells, histiocytes and eosinophils (Figure 1). RS cells
were CD20-, CD45- and CD30+. Fascin, which is not
specific for HL, but its negativity would make a diagnosis
of HL doubtful, stained most of the RS cells. A diagnosis
was made of “HL, classical type, mixed cellularity
subtype”. Positron emission tomography-computed
tomography (PET-CT) revealed additional LNs in the
cervical and supraclavicular region. Bone marrow biopsy
was negative for lymphoma. Serologic tests for hepatitis B,
C and HIV were negative. The patient was, thus, staged as
stage I, non-bulky HL, unfavourable, due to her age being
over 50. Combined therapy with four cycles of doxo-
rubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
chemotherapy followed by involved field irradiation was
scheduled. During chemotherapy, our patient experienced
respiratory difficulties which was not associated with
infection. Two control PET–CTs taken at the end of four
cycles of ABVD and at the end of 30.6 Gy/17 fractionated
radiotherapy to the right neck and supraclavicular region
showed complete remission. However, a routine third
PET-CT performed 3 months following completion of
chemoradiotherapy, revealed several fluorodeoxyglucose
(FDG) enhancing mediastinal LNs (Figure 2). There was
also FDG-enhancing thickening of the pleura in the left
lung laterobasal segment and an ill-defined increase in
parenchymal density. The findings were interpreted as
stronglylikelytoberecurrentlymphomaandthepossibility
of high-dose chemotherapy with autologous stem cell
transplantation was discussed with the patient. To confirm
the diagnosis, a mediastinoscopic LN biopsy was per-
formed. The LN architecture was completely effaced by
tightly packed non-caseating granulomas, indicating sarcoi-
dosis (Figure 3). There was no histological evidence of HL.
The patient was then referred to a chest physician for
consultation. A tuberculin test was negative. Carbon
dioxide diffusion was slightly reduced. Based on the clinical
and radiological findings, the patient was diagnosed with
sarcoidosis and steroid therapy was initiated.
Figure 1. The low power view of the lymph node shows an
effaced nodal architecture. There is a mottled appearance due
to lighter staining histiocyte-rich areas and darker staining
sheets of small mature appearing lymphocytes.
Figure 2. Positron emission tomography-computed
tomography image showing hypermetabolic mediastinal
lymph nodes.
Figure 3. The mediastinal lymph node, excised after
completion of doxorubicin, bleomycin, vinblastine, and
dacarbazine therapy, was significant for complete architectural
effacement by tightly packed granulomas.
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The second patient was a 49-year-old woman who was
diagnosed with diffuse large B cell lymphoma of germinal
centre origin in an axillary LN biopsy (CD20+, bcl-6+,
CD10+). Additional small LNs of 1.2 cm and 1.5 cm
diameter were identified in the thoracic and abdominal
cavities. There was neither bone marrow involvement nor
hepatosplenomegaly. Serologic tests for hepatitis B, C and
HIV were negative. She was staged as IIIA and put on
rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisolone (R-CHOP) chemotherapy. After four courses
of R-CHOP, there was regression in the enlarged peri-
pheral LNs but not in those of the abdomen and
mediastinum. The therapy was extended to a total of
eight courses with no response. A PET-CT confirmed the
hypermetabolic status of the non-regressing LNs as likely
indicating persistent lymphoma. A mediastinoscopic LN
biopsy was performed to confirm the diagnosis. However,
it revealed diffuse replacement by sarcoidal type non-
necrotizing granulomas with no histological evidence of
lymphoma. The patient was consequently referred to a
chest physician for further evaluation. No therapy for
sarcoidosis was instituted since the patient was asympto-
matic and had no pulmonary parenchymal involvement.
Discussion
These two cases clearly illustrate that not every ‘PET-
positive’ lesion represents malignancy and a tissue biopsy
is mandatory to confirm the diagnosis. Sarcoidosis is a
poorly understood idiopathic disease which is classically
defined as the occurrence of non-caseating granulomatous
inflammation in the absence other conditions such as
infection and malignancy. There are, however, some cases
of sarcoidosis reported to occur in association with a
broad spectrum of diseases, ranging from Hodgkin’s and
non-Hodgkin’s lymphomas, germ cell tumours, carcino-
mas to autoimmune diseases and therapy with immuno-
modulatory drugs. Therefore, some authors prefer to use
the terms ‘sarcoid-like lymphadenopathy’ or ‘sarcoidal
reaction’ instead of ‘sarcoidosis’ to describe lymph node
enlargement withnon-caseating granulomas inthe context
of malignancy or infection [1].
Sarcoidosis is considered as a type of florid cell mediated
immune reaction by histiocytes. In vivo/vitro anergy,
corresponding to cytotoxic T cell defect and increased T
helper cell activity, has been reported to be consistent with
defective cellular immunity [2]. Increased T helper cell
activity may represent a positive feedback loop, which
under normal circumstances would be silenced by signals
from activated cytotoxic T cells [3]. In this instance, the
exuberant histiocytic reaction may well represent a
physiologic substitution to the T cell defect, mediated by
increased T helper cell activity. The extent of this reaction
may be determined by additional factors, most impor-
tantly a triggering stimulus, which may be exogenous,
tumour or self antigens.
Classical signs of sarcoidosis start in the pulmonary
system. It is interesting that well recognised examples of
silicosis may be indistinguishable from sarcoidosis on
light microscopy only, further implicating the role of
antigenic stimuli that may trigger sarcoidosis. Therefore,
while some cases diagnosed as sarcoidosis may actually
be pneumoconiosis, a typical sarcoidosis may represent
interplay between the abnormal host immune system and
triggering antigens of specific immunogenic potential [4].
This overlap suggests that the T cell defect shown in
sarcoidosis is contributory but not essential in the
formation of florid granulomas.
When we search through the sarcoidosis–malignancy
association in the literature, sarcoidosis plays the most
frequent association with HL among haematopoietic
malignancies and with germ cell tumours among non-
haematopoietic malignancies [5,6]. This predilection
endows a critical role to specific tumour antigens in the
pathogenesis of sarcoidosis, suggesting that HL and
seminoma antigens are more ‘sarcoidogenic’ than others.
Localised sarcoidal reactions in lymph nodes draining the
site of the malignancy are the most frequent if not
exclusive presentation in malignancies. The temporal
relation of malignancies and sarcoidosis varies; they may
precede, follow or co-exist with malignancies [5]. Systemic
sarcoidosis increases the risk of HL. This is likely due to the
underlying immune deficiency permitting uncontrolled
Epstein-Barr virus (EBV) expansion, an oncogenic virus
frequently indicated in the aetiology of HL. There are rare
examples of sarcoidosis occurring after successfully treated
HL, similar to one of our patients [7].
Systemic sarcoidosis or localised reactions are also seen
after therapy with immuno-modulator agents. Interferon
therapy for Hepatitis C infection may cause sarcoidosis
with pulmonary and/or cutaneous involvement [8]. While
cessation of therapy resulted in regression in drug induced
cases, in patients with pre-existing sarcoidosis, interferon
had caused exacerbation with a lesser effect upon with-
drawal of the drug. Similar situations are reported in
rheumatoid arthritis patients treated with the TNF-a
antagonist etanercept, or even in solid organ transplant
patients under a high dose of immunosuppression [9,10].
Immunomodulatory agents interfere with the balance
between the varying components of the immune system.
When combined with the drug induced release of
viral particles in hepatitis C or self antigens in auto-
immune diseases, they seem to be sufficient to induce
sarcoidosis.
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triggering factors in a susceptible host, rather than a
homogenous disease with a specific aetiology. We propose
here two synergistic mechanisms in the formation of
exuberant non-caseating granulomas that define sarcoi-
dosis. This includes T cell dysfunction and exposure to
antigens, not readily degradable by other means, regard-
less of whether they are foreign, tumour associated or self
antigens. This hypothesis, which we basically predict from
our observations and from the limited knowledge in the
literature, needs to be verified by further research.
Conclusions
In our patients, immunosuppression intrinsic to their
lymphoma, accentuated by chemotherapy, superimposed
with the release of abundant tumour antigens may explain
the formation of sarcoidosis. In the patient with HL, we
hypothesize that sarcoidosis might be the underlying
reason for the unexplained respiratory difficulty experi-
enced during treatment. Release of abundant tumour
antigens during chemotherapy might have triggered a
sarcoidal reaction which was initially suppressed by the
ongoing therapy and became clinically evident thereafter.
Abbreviations
ABVD, doxorubicin, bleomycin, vinblastine, and dacarba-
zine; EBV, Epstein-Barr virus; FDG, fluorodeoxyglucose;
HL, Hodgkin’s lymphoma; LN, lymph node; PET-CT,
positron emission tomography-computed tomography;
R-CHOP, rituximab, cyclophosphamide, doxorubicin,
vincristine, prednisolone; RS, Reed-Sternberg.
Consent
Written informed consent was obtained from the patients
for publication of these case reports and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
OO performed the histopathological examination of the
lymph nodes and bone marrow, and was a major
contributor in writing the manuscript. MCA, HB, AEE,
and BF interpreted the patients’ data in terms of
haematological disease; MCA and BF also took part in
writing the manuscript. FT analysed and interpreted the
patients’ data regarding the infectious lung disease. GO
analysed and interpreted the patients’ data and clinical
findings related to sarcoidosis. All authors read and
approved the final manuscript.
Acknowledgements
There was no funding source for these case reports.
References
1. Trump DL, Ettinger DS, Feledman MJ, Dragon LH: “Sarcoidosis”
and sarcoid-like lesions: Their occurrence after cytotoxic
and radiation therapy of testis cancer. Arch Intern Med 1981,
141:37-38.
2. Viale G, Codecasa L, Bulgheroni P, Giobbi A, Madonini E, Dell’Orto P,
Coggi G: T-cell subsets in sarcoidosis: an immunocytochem-
ical investigation of blood, bronchoalveolar lavage fluid, and
prescalenic lymph nodes from eight patients. Hum Pathol 1986,
17:476-481.
3. Co DO, Hogan LH, Il-Kim S, Sandor M: T cell contributions to the
different phases of granuloma formation. Immunol Lett 2004,
92:135-142.
4. Grunewald J, Eklund A: Studies of T-lymphocytes in pursuit of
sarcoidosis antigens. Lakartidningen 2002, 99:3508-3513, 3515.
5. Cohen PR, Kurzrock R: Sarcoidosis and malignancy. Clin Dermatol
2007, 25:326-333.
6. May M, Gunia S, Siegsmund M, Kaufmann O, Helke C, Hoschke B,
Wille AH: Coincidence of testicular germ cell tumor and
sarcoidosis: A diagnostic challenge. Urologe A 2006, 45:1176-
1180.
7. Merchant TE, Filippa DA, Yahalom J: Sarcoidosis following
chemotherapy for Hodgkin’s disease. Leuk Lymphoma 1994,
13:339-347.
8. Ramos-Casals M, Mañá J, Nardi N, Brito-Zerón P, Xaubet A, Sánchez-
Tapias JM, Cervera R, Font J; HISPAMEC Study Group: Sarcoidosis
in patients with chronic hepatitis C virus infection: analysis of
68 cases. Medicine 2005, 84:69-80.
9. Verschueren K, Van Essche E, Verschueren P, Taelman V,
Westhovens R: Development of sarcoidosis in etanercept-
treated rheumatoid arthritis patients. Clin Rheumatol 2007,
26:1969-1971.
10. Bartram U, Thul J, Bauer J, Wössmann W, Schranz D: Systemic
sarcoidosis after cardiac transplantation in a 9-year-old child.
J Heart Lung Transplant 2006, 25:1263-1267.
Page 4 of 4
(page number not for citation purposes)
Journal of Medical Case Reports 2009, 3:7306 http://jmedicalcasereports.com/jmedicalcasereports/article/view/7306
Do you have a case to share?
Submit your case report today
￿ Rapid peer review
￿ Fast publication
￿ PubMed indexing
￿ Inclusion in Cases Database
Any patient, any case, can teach us
something
www.casesnetwork.com